Clinical Review

Using Electronic Pharmacy Intervention to Optimize Adherence to Beta-blocker Therapy in Patients With Heart Failure

Author and Disclosure Information

Cardiology research, including landmark trials, has demonstrated that 3 beta-blockers (BBs), bisoprolol, carvedilol, and metoprolol succinate, reduce mortality in heart failure (HF) patients.1-6 As a result, National Clinical Practice Guidelines strongly recommend using 1 of 3 BBs proven to reduce mortality in all stable patients who have current or prior symptoms of HF and reduced left ventricular ejection fraction (EF), unless contraindicated (Class I, Level of evidence A).7-8


 

Recommended Reading

Effect of High Left Ventricular Ejection Fraction in Older Women
Federal Practitioner
Allopurinol Use and Heart Failure Morbidity and Mortality
Federal Practitioner
Slo-Niacin Gets to the "Heart" of the Matter
Federal Practitioner
Pericardial Effusion: How Much Does Size Matter?
Federal Practitioner
ACS Patients Missing Out on Lipid Therapy
Federal Practitioner
Using Renal Disease to Predict Cardiovascular Risk
Federal Practitioner
Antidepressant Use: No Increased Risk of Myocardial Infarction (MI)
Federal Practitioner
PTSD May Lead to Higher Risk of Heart Disease
Federal Practitioner
The Triumphs and Tribulations of Establishing a Nurse-Run Chronic Disease Management Program in a Large VA Health Care Facility
Federal Practitioner
Recent Study Finds Suicide Among Veterans All Too Common
Federal Practitioner